These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9034935)

  • 1. Efficacy of ursodeoxycholic acid in combination with interferon-alpha in treating chronic hepatitis C: results of a long-term follow-up trial.
    Tanaka K; Kondo M; Sakaguchi T; Saito S; Arata S; Ikeda M; Kitamura T; Morimoto M; Sekihara H
    J Gastroenterol Hepatol; 1996 Dec; 11(12):1155-60. PubMed ID: 9034935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy of interferon-alpha and ursodeoxycholic acid in treatment of chronic type C hepatitis.
    Senturk H; Uzunalimoglu O; Batur Y; Simsek I; Mert A; Ozbay G; Cetinkaya H; Ersoz G; Tabak F; Akbaylar H; Akdogan M; Dokmeci A; Sonsuz A; Ozenirler S; Erden E; Tozum N
    Dig Dis Sci; 1997 Jul; 42(7):1438-44. PubMed ID: 9246043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients.
    Boucher E; Jouanolle H; Andre P; Ruffault A; Guyader D; Moirand R; Turlin B; Jacquelinet C; Brissot P; Deugnier Y
    Hepatology; 1995 Feb; 21(2):322-7. PubMed ID: 7843700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of interferon-alpha plus ursodeoxycholic acid versus interferon plus placebo in patients with chronic hepatitis C resistant to interferon.
    Poupon RE; Bonnand AM; Queneau PE; Trépo C; Zarski JPí ; Vetter D; Raabe JJ; Thieffin G; Larrey D; Grangé JD; Capron JP; Serfaty L; Chrétien Y; St Marc Girardin MF; Mathiex-Fortunet H; Zafrani ES; Guéchot J; Beuers U; Paumgartner G; Poupon R
    Scand J Gastroenterol; 2000 Jun; 35(6):642-9. PubMed ID: 10912666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of combination therapy of interferon-alpha with ursodeoxycholic acid in chronic hepatitis C: a randomized controlled clinical trial.
    Kiso S; Kawata S; Tamura S; Imai Y; Inui Y; Nagase T; Maeda Y; Yamasaki E; Tsushima H; Igura T; Himeno S; Seki K; Matsuzawa Y
    J Gastroenterol; 1997 Feb; 32(1):56-62. PubMed ID: 9058296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of ursodeoxycholic acid in the treatment of patients with chronic hepatitis C.
    Lu CL; Chan CY; Hwang SJ; Lu RH; Lee SD
    J Gastroenterol Hepatol; 1995; 10(4):432-7. PubMed ID: 8527710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of ursodeoxycholic acid in association with alpha-interferon for chronic hepatitis C in alpha-interferon non-responder patients.
    Fabbri C; Marchetto S; Pezzoli A; Accogli E; Fusaroli P; Azzaroli F; Jaboli MF; Mazzeo C; Montagnani M; Festi D; Roda E; Mazzella G
    Eur J Gastroenterol Hepatol; 2000 May; 12(5):511-5. PubMed ID: 10833093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up.
    Angelico M; Gandin C; Pescarmona E; Rapicetta M; Del Vecchio C; Bini A; Spada E; Baroni CD; Capocaccia L
    Am J Gastroenterol; 1995 Feb; 90(2):263-9. PubMed ID: 7847298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon plus ursodeoxycholic acid versus interferon in the treatment of chronic C viral hepatitis.
    Clerici C; Distrutti E; Gentili G; Solinas A; Miglietti M; Balò S; Giansanti M; Rusticali AG; Morselli-Labate AM; Morelli A
    Minerva Med; 1997 May; 88(5):219-25. PubMed ID: 9250283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of interferon, ribavirin and ursodeoxycholic acid in patients with hepatitis C infection.
    Ljubuncic P; Konikoff FM; Blendis LM; Bomzon A
    Hepatogastroenterology; 2005; 52(64):1191-6. PubMed ID: 16001659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease.
    Lirussi F; Beccarello A; Bortolato L; Morselli-Labate AM; Crovatto M; Ceselli S; Santini G; Crepaldi G
    Liver; 1999 Oct; 19(5):381-8. PubMed ID: 10533795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of alanine aminotransferase by administration of suplatast tosilate plus ursodeoxycholic acid in patients with resistance to ursodeoxycholic acid monotherapy on hepatitis C virus-related chronic liver disease.
    Matsuda Y; Inada M; Maeda H; Matsuyama T
    Intern Med; 2002 Oct; 41(10):774-9. PubMed ID: 12412994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C.
    Orito E; Mizokami M; Suzuki K; Ohba K; Ohno T; Mori M; Hayashi K; Kato K; Iino S; Lau JY
    J Med Virol; 1995 Jun; 46(2):109-15. PubMed ID: 7636496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients.
    Tsubota A; Kumada H; Arase Y; Chayama K; Saitoh S; Ikeda K; Kobayashi M; Suzuki Y; Murashima N
    Eur J Gastroenterol Hepatol; 1999 Oct; 11(10):1077-83. PubMed ID: 10524635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C.
    Omata M; Yoshida H; Toyota J; Tomita E; Nishiguchi S; Hayashi N; Iino S; Makino I; Okita K; Toda G; Tanikawa K; Kumada H;
    Gut; 2007 Dec; 56(12):1747-53. PubMed ID: 17573387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment.
    Campistol JM; Esforzado N; Martínez J; Roselló L; Veciana L; Modol J; Casellas J; Pons M; de Las Cuevas X; Piera J; Oliva JA; Costa J; Barrera JM; Bruguera M
    Nephrol Dial Transplant; 1999 Nov; 14(11):2704-9. PubMed ID: 10534516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of chronic hepatitis C with interferon with or without ursodeoxycholic acid: a randomized prospective trial.
    Abdelmalek MF; Harrison ME; Gross JB; Poterucha JJ; Gossard AA; Spivey JR; Rakela J; Lindor KD
    J Clin Gastroenterol; 1998 Mar; 26(2):130-4. PubMed ID: 9563925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
    Tarao K; Fujiyama S; Ohkawa S; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Tanaka K
    Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.
    Sarrazin C; Rouzier R; Wagner F; Forestier N; Larrey D; Gupta SK; Hussain M; Shah A; Cutler D; Zhang J; Zeuzem S
    Gastroenterology; 2007 Apr; 132(4):1270-8. PubMed ID: 17408662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.